Anti-αvβ3 Integrin Recombinant Antibody (TAB-705)

Customer Review

There are currently no Customer reviews or questions for TAB-705. Click the button above to contact us or submit your feedback about this product.

Great Specificity

The specificity of Etaracizumab towards αvβ3 integrin is outstanding. It has minimized cross-reactivity issues we encountered with other antibodies, leading to more accurate results.

Great for Flow Cytometry

Etaracizumab worked exceptionally well in our flow cytometry assays. It helped us accurately quantify αvβ3 integrin on different cell types, aiding our cellular analysis projects.

Reliable Conjugation

We conjugated Etaracizumab with Alexa Fluor and achieved clear, bright staining in our imaging studies. It's a reliable option for those needing fluorescent labeling for visualization.

Q&As

1. Is it possible to utilize etaracizumab in a typical ELISA assay?

   A: Yes, Etaracizumab can be used in an ELISA assay to detect the presence of αvβ3 integrin in various samples, offering reliable and sensitive results for research purposes. Optimization may be required for different sample types.

2. Is it possible to conjugate this antibody with fluorescent dyes for imaging purposes?

   A: Absolutely, Etaracizumab can be conjugated with various fluorescent dyes, such as FITC or Alexa Fluor, to facilitate imaging and visualization of αvβ3 integrin in cellular and tissue samples.

3. Does Etaracizumab work well in applications involving flow cytometry?

   A: Yes, Etaracizumab can be used in flow cytometry to analyze the expression of αvβ3 integrin on the surface of various cell types. Proper optimization of staining protocols may be necessary.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Bayat, Behnaz, et al. "Current anti-HPA-1a standard antibodies react with the β3 integrin subunit but not with αIIbβ3 and αvβ3 complexes." Thrombosis and haemostasis 119.11 (2019): 1807-1815. https://doi.org/10.1055/s-0039-1696716
   This research investigated the reactivity patterns of anti-HPA-1a standard antibodies used for diagnosing and predicting fetal/neonatal alloimmune thrombocytopenia (FNAIT) severity. Using flow cytometry, adsorption experiments, and functional assays, the study demonstrated that current standard materials (NIBSC 03/152) and human monoclonal antibodies (26.4 and 813) primarily recognize epitopes on the β3 integrin subunit independently, rather than αIIbβ3 or αvβ3 complexes. Significantly, these antibodies lack reactivity with αvβ3 complexes that were predominantly found in severe FNAIT cases with intracranial hemorrhage (ICH). All tested standard antibodies failed to inhibit endothelial tube formation, unlike anti-HPA-1a antibodies from ICH-positive cases.
   Creative Biolabs supplied the therapeutic human monoclonal antibody etaracizumab (humanized murine moab LM609) which targets the αvβ3 complex for this research. This antibody served as a critical control, demonstrating strong reactivity with αvβ3 and completely blocking endothelial tube formation in functional assays, unlike the anti-HPA-1a standard antibodies. The inclusion of etaracizumab helped establish the distinct binding profiles of different antibody subtypes and highlighted the absence of anti-αvβ3 activity in current standard materials, revealing a significant limitation in their ability to predict severe FNAIT cases with intracranial hemorrhage risk.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-705, RRID: AB_3111984)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Publications

Our products have been used extensively by scientists all over the world to accelerate their life science research. Here, we present a collection of publications that cite this product.

Bayat, Behnaz, et al. "Current Anti-HPA-1a Standard Antibodies React with the β3 Integrin Subunit but not with αIIbβ3 and αvβ3 Complexes." Thrombosis and haemostasis 119.11 (2019): 1807-1815.

Biosimilar Overview

Please refer to Etaracizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Etaracizumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "αVβ3 integrin"

Select a product category from the dropdown menu below to view related products.